Drug intelligence / Profile preview

VGN-R09b

Development stage: Phase 2
Lead developer: Shanghai Vitalgen BioPharma
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intraparenchymal

Overview

VGN-R09b is an adeno-associated virus (AAV)-based gene therapy developed for the treatment of Parkinson's disease and aromatic L-amino acid decarboxylase (AADC) deficiency. The therapy utilizes an AAV9 vector to deliver a functional copy of the DDC gene, which encodes aromatic L-amino acid decarboxylase, directly into the striatum via intraparenchymal injection. This approach aims to restore or enhance dopamine synthesis in patients with dopamine-related disorders by increasing AADC enzyme activity in targeted brain regions. The drug is currently in Phase 1/2 clinical trials for Parkinson's disease and early-phase trials for AADC deficiency[1][3][5][6].

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on VGN-R09b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGN-R09b.

Explore the full profile